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TECHNICAL NOTE
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Serum oxalate microassay using chemiluminescence detection. Deter-
mination of serum oxalate Concentration is important for the diagnosis
and monitoring of hyperoxalurias, and extends to patients with all types of
renal disease. Approximately 5 to 10 ml of blood is required for each test
by conventional methods, and the test is not adapted for use in children.
We developed a highly sensitive method that limits the volume of blood
required for the test. This new and sensitive tool to detect H202 can be
successfully substituted for the conventional, and expensive, colorimetric
reaction to accurately analyze oxalate concentration.
The determination of serum oxalate concentration is challeng-
ing because of its low normal range, interfering substances and
spontaneous in vitro oxalogenesis [1—3]. Previous reports using in
vitro assays provided higher normal serum oxalate concentrations
than those obtained from in vivo radioisotopic dilution methods
[3, 4]. More recently, high performance ion-chromatography and
enzymatic methods together with improvements in sample pro-
cessing have allowed us to obtain reliable analytical methods [2, 5,
6].
Most methods for oxalate measurement are expensive, techni-
cally demanding and time consuming. The determination of
serum oxalate concentration is of great interest in the diagnosis
and the monitoring of hyperoxalurias, mainly primary hyperox-
aluria type 1 (PHi), which is a rare autosomal recessive inborn
error of glyoxylate metabolism due to a functional defect of the
liver enzyme alanine:glyoxylate aminotransferase [7]. Moreover,
the importance of the determination of serum oxalate extends to
all types of renal patients. Available oxalate measurement meth-
ods require 5 to 10 ml of blood for each test, and is not adapted
to children, which is particularly crucial for post-transplantation
biochemical monitoring.
We therefore developed an analytical method with a high
sensitivity that allows a limitation of the blood sample volume.
The enzymatic method used oxalate oxidase (EC 1.2.3.4.) coupled
with a colorimetric detection system. In the presence of oxalate
oxidase, oxalate is converted into CO2 and H202; as a second step,
H202 is converted to 02 and H20 in the presence of additional
peroxidase (EC 1.11.1.7). 02 then reacts with a 3-methyl-2-
henzothiazolinone hydrazone and 3-dimethylaminobenzoic acid
Key words: oxalate assay, serum oxalate assay, chemiluminescencc.
Received for publication March 6, 1997
and in revised form July 21, 1997
Accepted for publication July 21, 1997
© 1997 by the International Society of Nephrology
to form a colored complex with a 580 nm absorption [2, 6, 8]. In
addition, it has recently been shown that metal porphyrins can
catalyze luminol chemiluminescence in the presence [9—11] or in
the absence [12] of hydrogen peroxide, according to the condition
of the assay. The oxidation of luminol (5-amino-2,3 dihydro-1,4-
phtalazine dione) subsequently results in aminophtalate ion for-
mation in an exited state that emits photons upon decay. In our
study, this new sensitive tool to detect H202 has been successfully
substituted to the colorimetric reaction in order to obtain a
sensitive analytical method for oxalate analysis (Fig. 1).
METHODS
Chemicals and chemiluminescence measurement
instrumentation
All solutions were prepared with ultra-pure water (resistivity>
18 M1 cm) obtained from a reverse osmosis and ion exchange
purification system (Elgastat UHQ, Elga, France).
The enzymatic reagent (oxalate oxidase from barley seedlings;
Sigma Chemical Co., St. Louis, MO, USA) was prepared by
resuspended oxalate oxidase in succinic buffer (succinic acid 45
mmol/liter, EDTA 3.3 mmol/liter, pH 3.8) in order to give a 55
U/liter final concentration.
The porphyrin (Fe mesotetra [4 sulfonatophenyl] porphine;
Porphyrin Products Inc., Logan, UT, USA) was solubilized in
water (30 mg into 10 ml). The porphyrin solution was further
mixed with 500 mg of chelating resin (Chelex 100; Sigma Chem-
ical Co.) in order to remove free iron. Luminol (5-amino-2,3
dihydro-1,4-phtalazine dione; Boehringer Mannheim Gmbh) was
purified by recrystallization from NaOH 1 mol/liter [13] and
solubilized in DMSO (dimethyl sulfoxide; Sigma Chemical Co.) in
order to obtain a 8 mmol/liter solution. The chemiluminescent
reagent was prepared by diluting 10 j.tl luminol solution and 1 ml
porphyrin solution into 100 ml glycine buffer (50 mmol/liter, pH
10.45). After helium degassing, the final solution was packaged in
light- and air-protected glass syringe; when stored at +4°C the
reagent was stable for 20 days. For analysis, the syringe containing
the chemiluminescent reagent was directly connected to a pipet-
ting station by a luer lock connection to protect it from air.
Chemiluminescent measurements were carried out in 11.5 >< 55
mm test tubes using an Optocom-1 luminometer (MGM Instru-
ments, Hamden, CT, USA). Emitted photons were counted
during a five second period and the results were expressed as
relative light units (1 RLU = 10 counts).
Analytical procedure
Whole blood (minimum 0.5 ml) was drawn from vein puncture
into a Vacutainer tube (without additive) that was stored in
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Fig. 2. Relative light units (RLU) versus oxalate concentration for
normal patient serum (13 mol/liter) and three different spikes (2, 4 and
10 mol/liter) illustrated the sensitivity and the linearity of the method in
the low oxalate concentration range.
crushed ice. To avoid in vitro oxalogenesis [1—3], the blood sample
was processed within 90 minutes after collection as follows: the
blood sample was immediately centrifuged (1800 x g for 10 mm)
at 4°C, and 200 .d of serum were diluted in 1.8 ml of a buffer
solution (succinic acid 45 mmol/liter, EDTA 3.3 mmol/liter,
NaNO2 250 imolIliter, pH 3.8). The final sample could be stored
at —20°C.
For the oxalate assay, 50 .d of the sample were incubated at
+ 37°C with 200 1.d of the freshly prepared oxalate oxidase
dilution. After 30 minutes, the enzymatic reaction was stopped by
15 pi 5% NaOH. The resulting H202 was immediately measured
as follows: 10 1.d of incubation mixture were transferred together
with 200 pA of chemiluminescence reagent in a test tube by using
the pipetting station. Emitted photons were immediately counted
during five seconds.
Quantification of oxalate was performed by using a standard
addition method (successive measurements of serum with oxalate
spikes: 10, 20 and 40 mol/liter final concentration). A blank was
obtained in which the enzymatic reaction was initially stopped by
NaOH addition before the enzymatic incubation.
Statistics
Statistics used analysis of variance and paired or unpaired
f-test.
Fig. 1. Principle of the developed method for
assaying oxalate in serum
Table 1. Within- and between-assay precision studies for three
different sera
Within-assay Between-assay
Mean Mean
N imo1/1iter CV (%) N pinol/liter CV (%)
Serum 1 20 1.4 5.5 20 1.5 9.3
Serum 2 20 6.7 3.8 20 6.6 6.0
Serum 3 20 23.0 3.6 20 23.0 4.3
RESULTS
Analytical variables
The present serum oxalate microassay was evaluated according
to the validation protocol of the Société Française de Biologie
Clinique [14].
The detection limit (DL) was defined as the smallest concen-
tration signal that can be distinguished from a blank obtained in
the same condition. It could be calculated from the standard
deviation (SD) of the signal obtained for repeated measurements
of the blank (N = 30) using the formula DL = K X SD/AS [where
K is the coefficient depending on the number of blank replicates
(n) and a and 13 risk; SD, standard deviation of the blanks
expressed as signal units; AS, analytical sensitivity, that is, signal:
concentration]. With K = 4 (5% a risk and 10% f3 risk), SD = 108
RLU, AS = 1743 RLU X (j.imol/liter)1, the obtained detection
limit was 0.2 .tmol/liter. The same formula (K = 10) was applied
to determine the limit of quantitation 0.6 j.imol/liter, in the range
of which the precision was 12.6% (10 repeated measurements of
a 0.6 .tmol/1iter serum sample).
On the basis of diluted specimens, the method was shown to be
linear up to 160 jxmol/liter. The recovesy of added oxalate was
assessed by determination of oxalate prior to, and following, 5
imol/liter addition of oxalate to serum samples ranging from 1.1
to 7,7 .tmol/liter (N = 10). In such condition, the mean analytical
recovety of oxalate was 97% (SD 5%).
Figure 2 illustrates the sensitivity and the linearity of the
method. The within- and between-assay coefficients of variation
for three different sera (serum samples spiked with oxalate) are
reported in Table 1.
To investigate ascorbate interference, serum samples (N 12)
were spiked together with ascorbate (250 and 500 xmol/liter final
concentration). With or without ascorbate addition, serum oxalate
measurements were not significantly different (P < 0.05).
To assess the effect of frozen storage, six fresh serum samples
(ranging from 1.8 to 3.8 j.mol/liter) were tested as follows in
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Fig. 3. Serum oxalate concentration in normal subjects (N 60).
preliminary studies. Each serum was divided into three aliquots:
the first one was promptly analyzed; the second and the third ones
were pretreated and stored at —20°C in order to be analyzed 20
days later; the third aliquot was initially supplemented with
ascorbate (500 xmol/liter). There was no evidence of oxalate loss
nor in vitro oxalogenesis during the storage period (P < 0.05).
Clinical results
Normal adult serum oxalate values were determined from
serum samples of 30 apparently healthy staff (age 22 to 55 years).
Each subject had normal chemistry profile including serum cre-
atinine and none had a history of kidney stones disease, bowel
disease or malabsorption. The mean serum oxalate concentration
was 1.8 ixmol/liter (SD 1.0 jxmol/hter) and the mean serum
oxalate:creatinine ratio was 0.022 (SD 0.012); there was no sex
difference and there was no correlation with age. Serum oxalate
concentration was also determined in a normal pediatric popula-
tion (N = 30, age 0.5 to 15 years). These children were admitted
for diseases unrelated to renal, liver or gastrointestinal dysfunc-
tion and were regarded as controls after clinical and biochemical
screening. The remaining serum after routine biochemistry deter-
mination was used for oxalate measurements. Defined samples
treatment conditions (process delay and storage in crushed ice)
were respected. Serum oxalate concentration was 3.3 xmol/liter
(SD 1.7 jxmol/liter) and serum oxalate:creatinine ratio was 0.058
(SD 0.035). Again, no sex difference was noted and serum oxalate
values did not correlate with age in this group (P < 0.05). The
population characteristics and the observed results are reported in
Table 2 and Figure 3.
In addition, the serum oxalate concentration of patients with
various renal diseases was determined and ranged from 2.6 to 54.4
jxmol/liter. Patients with PHi (N = 5; 4 children, I adult)
experienced a very high serum oxalate concentration (16.9, 22.4,
34.9, 51.7 and 54.4 jxmol/liter).
DISCUSSION
The present results are comparable to those obtained from
radioisotopic [4], chromatographic [5] and enzymatic reference
methods [2, 6, 8], although additional data and correlation studies
with these standard methods arc required to confirm this agree-
ment. Moreover, the assay appears to be free of ascorbate
interference due to sample processing using sodium nitrite (2],
since ascorbate addition (up to 500 xmol/liter) does not affect
oxalate concentration; there was no change in assay sensitivity
(risk of oxalate oxidase activity inhibition) nor in the apparent in
vitro oxalogenesis. On the basis of a 200 jxl serum sample, our goal
to allow investigation of hyperoxaluric states in children was
achieved.
Barratt et al have reported reference values in children that
were not significantly different from those obtained in adults [15j.
The mean serum oxalate concentration was 1.53 (range 0.78 to
3.02) xmol/liter and the oxalate:creatinine ratio was 0.033 (se
0.013). These reference values are slightly lower than ours. In
addition, we found significantly higher oxalate serum concentra-
tion in children than in adults; however, despite a significant
difference in the average serum oxalate concentration in the two
age groups, we did not find any significant correlation with age by
regression analysis when all oxalate concentration values were
plotted together (Fig. 3). In addition, we did not observe the log
correlation that was found by Barratt et al between serum oxalate
and serum creatinine concentrations [15].
In conclusion, the present microassay using oxalate oxidase
coupled with chemiluminescence detection for serum oxalate
concentration measurement is simple, inexpensive and reliable.
The small blood volume required makes it particularly adaptec!
for diagnosis and monitoring of both children and adults with
hyperoxaluria.
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